For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development | 151,389 | |||
| General and administrative | 40,017 | |||
| Total operating expenses | 191,406 | |||
| Loss from operations | -191,406 | |||
| Interest income | 23,611 | |||
| Total other income | 23,611 | |||
| Net loss | -167,795 | |||
| Unrealized gain on available-for-sale securities | 257 | |||
| Total comprehensive loss | -167,538 | |||
| Basic EPS | -1.63 | |||
| Diluted EPS | -1.63 | |||
| Basic Average Shares | 102,930,744 | |||
| Diluted Average Shares | 102,930,744 | |||
Edgewise Therapeutics, Inc. (EWTX)
Edgewise Therapeutics, Inc. (EWTX)